- Home
- STEM vs PLX Comparison
STEM vs PLX Comparison
Compare STEM & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STEM | PLX |
|---|---|---|
| Founded | 2009 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.9M | 230.0M |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | STEM | PLX |
|---|---|---|
| Price | $9.56 | $2.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $14.60 | $12.00 |
| AVG Volume (30 Days) | 165.6K | ★ 1.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $144,584,000.00 | $53,399,000.00 |
| Revenue This Year | $5.48 | $9.67 |
| Revenue Next Year | $12.51 | $23.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.29 | $1.34 |
| 52 Week High | $32.23 | $3.19 |
Technical Indicators
Market Signals| Indicator | STEM | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 26.52 | 53.92 |
| Support Level | $0.38 | $1.39 |
| Resistance Level | $21.86 | $3.03 |
| Average True Range (ATR) | 0.77 | 0.16 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 7.18 | 21.59 |
Price Performance
Historical ComparisonAbout STEM Stem Inc.
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.